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uring virologic failure. Genotypic assays are generally pre-
erred because of cost and rapidity, except in situations
here multiple ART regimens have been used, when phe-
otypic assays may be of value.
When abacavir is being considered as part of an ART
egimen, genetic screening for HLAB* 5701 is helpful to
educe the risk of severe abacavir hypersensitivity reac-
ions. These reactions, reported in 5-8% of white and 2-3%
f black patients occur primarily in individuals with the MHC
lass I allele HLA-B*5701. Individuals who screen positive for
LA-B*5701 should not receive abacavir.
When a CCR5 antagonist (e.g., maraviroc) is being con-
idered as part of an ART regimen, a coreceptor tropism
ssay is useful, since an agent of this class will only suppress
iruses that utilize this receptor (R5 viruses). CCR5 antago-
ists should not be used in individuals who carry primarily X4
r dual/mixed tropic viruses. Currently, the principal assay
vailable to measure HIV-1 tropism is phenotypic, though
enotypic tests are under study.
Although therapeutic drug monitoring is recommended
y some, its use remains controversial, and no clear-cut
ecommendations can be made regarding its utility.
oi:10.1016/j.ijid.2010.02.2188
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Despite the important advance that cART represents for
he prognosis of the HIV-1 infection, OIs continue to be an
mportant cause of morbidity and mortality in developed
ountries. This is due to late presentation (up to one-third
f new HIV-1 infections), lack of adherence to cART and
rophylaxis or virological failure of cART. In addition, OIs
re very common in developing countries, being tubercu-
osis (TB) the most common one. The ACTG A5164 results
ecommended to start cART during the ﬁrst 2 weeks after
tarting antimicrobial treatment for the OI (patients with
B were not included in this RCT). Some of these patients,
espite having an excellent viral and immune response to
ART, will present a paradoxical worsening of the OI known
s the immune reconstitution inﬂammatory syndrome (IRIS).
he microorganisms most commonly associated with IRIS are
ycobacteria, fungi, and herpes group viruses. The IRIS has
lso been reported in tumors, such as Kaposi sarcoma, and
auses autoimmune diseases. The percentage of patients
ho develop IRIS is variable. In cohort studies of patients
tarting cART, IRIS affects between 15% and 25%. In OIs series
ike TB the frequency is higher, and can reach 50%. Clini-
al effects of IRIS range from a mild, self-limiting illness to
evere morbidity and mortality. The lack of evidence-based
reatment guidelines poses challenges in the management
f these patients. Patients are generally recommended to
ontinue with cART and speciﬁc treatment against OIs.
djuvant nonsteroid anti-inﬂammatory drugs (NSAIDs) and
orticosteroids are commonly used. Corticosteroids have
emonstrated their usefulness in a recent clinical trial in
B patients. Surgery is necessary to debride abscesses.
s
o
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n life-threatening cases, the possibility of interrupting
ART should be considered until the patient’s situation has
mproved. Clinical experience with immunosuppressors or
NF-alpha inhibitors is very limited.
oi:10.1016/j.ijid.2010.02.2189
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Community-acquired pneumonia (CAP) is a serious health
roblem worldwide with an annual incidence of 0.3-0.5%
n the adult population. Besides, CAP remains the leading
ause of death from infectious diseases. This justiﬁes the
nterest in studying all clinical aspects affecting CAP. A new
pproach is to evaluate biological markers of infection and
nﬂammation, as an expression of the hostˇıs inﬂammatory
esponse against the microorganism, in order to achieve
iagnosis, aetiology, progonosis and treatment informa-
ion. The most widely studied biomarkers have been C
eactive protein (CRP), procalcitonin (PCT) and cytokines.
ther biomarkers are now obtaining promising results. Most
uthors conclude that biomarkers can help in the diagno-
is of CAP. Fewer data analyse the capacity of biomarkers
n identiﬁying the potential causative agent and the best
esults have been settled down in children. Linked with the
bove mentioned, biomarkers, mainly PCT, have been used
uccesfully guiding antibiotic prescription in patients with
uspected CAP. Treatment guided by serum PCT was a safe
ay to avoid antibiotics, although economic savings were
vershadowed by PCT analysis costs. Approximately 10-15%
f patients hospitalised for CAP develop treatment failure
nd almost 6% may manifest rapidly progressive pneumonia,
t has been demonstrated that serum levels of biomarkers
an identify patients at risk of treatment failure and there-
ore could guide treatment handling. Clinical data scoring
ystems have been recognized as a useful tool to assess sta-
ility and prognosis of patients with CAP. Analysis of systemic
iomarkers in adition to clinical scores has shown to improve
ither the prediction of absence of severe complications
nd the 30-day mortality prediction by PSI or CURB65/CRB65
cales. Current data from literature seem to support the use
f biomarkers in the daily medical practice concerning CAP.
oi:10.1016/j.ijid.2010.02.2191
